Clinical Trial

Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)

Study acronym: FOLFIRINOX3
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
In patients in progression after oxaliplatin and irinotecan, the study FOLFIRINOX 3 proposes to evaluate the interest of modifying the standard pattern of administration of the molecule of irinotecan in order to make it more efficient. In combination with other chemotherapy drugs (5-fluorouracil, oxaliplatin, folinic acid and bevacizumab), irinotecan will be administered at the beginning and end of each cycle of chemotherapy, whereas it is normally administered at one time in the regimen. standard of treatment. The hypothesis of this study is an increase in the objective response rate at 2 months of 10 to 30% with a scheme by FOLFIRINOX3 - bevacizumab compared to an optimal treatment to date by FOLFIRINOX-bevacizumab.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2019-01-03; most recent amendment 2025-02-14.
Status change: Recruiting → Active, Not Recruiting 2023-10-16
Trial Details
NCT Number NCT03795311
Lead Sponsor Centre Georges Francois Leclerc
Conditions Colorectal Cancer
Enrollment 32 participants
Start Date 2018-11-07
Primary Completion 2023-01-16 (estimated)
Study Completion 2025-07-16 (estimated)
Updated on ClinicalTrials.gov 2025-02-17